Acumen has entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company. The loan agreement provides up to $50.0M principal in term loans consisting of a first tranche of $30.0M, which was funded at closing, and a second tranche of up to $20.0M which may be funded in installments upon the company’s request, subject to review by the lenders of certain information from the company and discretionary approval from the lenders. The loan matures on November 1, 2027 and may be extended to November 1, 2028 if the company achieves certain financing milestones.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABOS:
- Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
- Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
- ABOS Upcoming Earnings Report: What to Expect?
- Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
- Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023